Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring Minimal Residual Disease Based on Circulating Tumor DNA

NCT06157060 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT06157060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06157060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring Minimal Residual Disease Based on Circulating Tumor DNA
Lead sponsor
Zhujiang Hospital
Phase
Observational
Overall status
Recruiting
Start date
November 20, 2023
Completion date
November 30, 2028
Enrollment
255 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma resectable